Parkinson hastalığı için glukagon benzeri peptid 1 agonistlerinin etkinliği ve güvenliği: sistematik bir inceleme ve meta-analiz.

Araştırma özeti

Aşağıdaki metin kaynak makalenin lisansı doğrulanmış orijinal özetidir. cc by

BackgroundRecent research on Parkinson's disease (PD) therapy has highlighted glucagon-like peptide 1 (GLP-1) agonists as potential therapeutic agents. However, recent randomized controlled trials (RCTs) have shown mixed results regarding the use of this medication.ObjectiveTo perform a meta-analysis comparing GLP-1 agonists with placebo or standard PD treatment in adult PD patients.MethodsWe systematically searched the PubMed, Embase and Cochrane Central databases. The efficacy outcomes were assessed through the Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS) and the 39-item Parkinson's Disease Questionnaire (PDQ-39). We also assessed adverse events. Dichotomous data were compared using the risk ratio (RR), and continuous endpoints were pooled using the mean difference (MD).ResultsWe included 4 RCTs, with a total of 514 patients. In every study, the Hoehn and Yahr stage was ConclusionIn 1 year, GLP-1 agonists failed to improve motor and non-motor features of PD. Additional high-quality studies are needed to draw more robust conclusions about this treatment.

İlgili konular